Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA). This study offers the opportunity to understand the safety, tolerability, and efficacy of CAD-1883 in the SCA patient population.


Clinical Trial Description

This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of SCA using multiple dose levels. The study will include multiple cohorts of 16 patients each where 12 patients will be randomized to CAD-1883 and 4 to matching placebo. Potential subjects will undergo a screening period (14 to 28 days), a baseline (Day 1) visit, and a 12-week treatment period. A follow-up visit will occur 4 weeks after the end of the treatment period. The total duration of individual subject participation may be up to 20 weeks, depending on the duration of the screening period. The study will assess safety by adverse events, vital signs, laboratory parameters (including chemistry, hematology and urinalysis); pharmacokinetics of CAD-1883; and efficacy measures by Scale for the Assessment and Rating of Ataxia (SARA), clinician/patient rating of ataxia and symptoms, patient quality of life measures and wearable sensors to capture falls and gait measurements. For planning purposes, the anticipated study completion date assumes evaluation of 3 cohorts. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04301284
Study type Interventional
Source Cadent Therapeutics
Contact
Status Withdrawn
Phase Phase 2
Start date June 2021
Completion date December 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05973019 - rTMS Improves Functions in Spinocerebellar Ataxia N/A
Completed NCT04837027 - Effect of Training on Brain Volume in Ataxia N/A
Completed NCT04595578 - Cerebellar rTMS and Physical Therapy for Cerebellar Ataxia N/A
Completed NCT03745248 - Aerobic Exercise, Balance Training, and Ataxia N/A
Completed NCT05951010 - Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia 38 N/A
Completed NCT01037777 - RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7
Completed NCT00136630 - Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
Completed NCT03687190 - Could Tai-chi Help Maintain Balance of Spinocerebellar Ataxia Patients N/A
Active, not recruiting NCT03701399 - Troriluzole in Adult Subjects With Spinocerebellar Ataxia Phase 3
Completed NCT05436262 - Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar Ataxia N/A
Recruiting NCT04231487 - Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders
Not yet recruiting NCT06397274 - Stemchymal® for Polyglutamine Spinocerebellar Ataxia Phase 2
Not yet recruiting NCT06177626 - Impact of Exercise on Eyeblink Conditioning in Spinocerebellar Ataxias N/A
Recruiting NCT04529252 - Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases
Completed NCT05621200 - Transcranial Alternating Current Stimulation (tACS) in Patients With Ataxia N/A
Completed NCT03701776 - Ataxia and Exercise Disease Using MRI and Gait Analysis N/A
Completed NCT03120013 - Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia N/A
Active, not recruiting NCT03408080 - Open Pilot Trial of BHV-4157 Phase 3
Active, not recruiting NCT02960893 - Trial in Adult Subjects With Spinocerebellar Ataxia Phase 2/Phase 3
Completed NCT04153110 - Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia N/A